Introduction
============

Chronic hepatitis C (CHC) has been considered a metabolic disease rather than just a viral disease as it is usually associated with impaired glucose tolerance, insulin resistance, steatosis and changes in lipid metabolism (Mehta et al., 2000\[[@R19]\]; Perlemuter et al., 2002\[[@R21]\]). The prevalence of insulin resistance (IR) and type 2 diabetes (T2D) has been demonstrated to be higher in chronic hepatitis C than non infected population (Torres and Harrison, 2008\[[@R28]\]). This finding was confirmed by studies shown that the IR in CHC patients is greatly improved after successful therapy of HCV (Simó et al., 2006\[[@R25]\]; Kawaguchi et al., 2007\[[@R14]\]). Furthermore, it has been demonstrated that IR and T2D hasten the progression of liver fibrosis and cirrhosis in CHC patients (Hui et al., 2003\[[@R12]\]; Fartoux et al., 2005\[[@R9]\]). Despite the close relationship between HCV infection and T2D, the underlying mechanisms that link both of them remain elusive.

Adipokines are diverse group of mediators secreted from the adipose tissue. They have a potential role in modulating the insulin sensitivity, immunity and inflammation (Rabe et al., 2008\[[@R22]\]). Adipokines have been reported to play an important role in pathogenesis of liver fibrosis and in the metabolic consequences of liver disorders, however their role is not fully elucidated (Bertolani and Marra, 2008\[[@R2]\]; Marra and Bertolani, 2009\[[@R17]\]; Yilmaz et al., 2011\[[@R34]\]). A study by Kukla et al. (2010\[[@R15]\]) has shown that serum adipokines (chemrin and leptin) were significantly higher in patients with chronic hepatitis C compared to healthy controls. Additionally, chemrin was inversely correlated with the inflammatory grade in CHC patients*.*

Omentin-1 (Intelectin-1) is a newly identified protein that is highly and selectively expressed in visceral adipose tissue (Schäffler et al., 2005\[[@R24]\])*.* Omentin-1 may act as an endocrine factor affecting muscles, liver and omental adipose depot to enhance insulin sensitivity and glucose metabolism (Yang et al., 2006\[[@R33]\])*.* Interestingly, circulating omentin-1 levels have been negatively correlated with obesity and insulin resistance (Pan et al., 2010\[[@R20]\]). Recently, a study by Yilmaz et al. (2011\[[@R34]\]) has demonstrated that serum omentin-1 is elevated in patients with fatty liver diseases and it represents an independent predictor for hepatocyte ballooning in those patients. Another study by Eisinger et al. (2013\[[@R7]\]) has reported that omentin-1 level is increased in liver cirrhosis but is not associated with complications of portal hypertension. However, the role of omentin-1 in the chronic hepatitis C and its metabolic consequences is unexplored yet. This led us to conduct the present study in which we investigated the levels of omentin-1 in sera of chronic hepatitis C patients, with and without type 2 diabetes, and compared them with its levels in healthy controls. Additionally, we evaluated the correlation of omentin-1 with IR and biochemical parameters of liver injury.

Materials and Methods
=====================

Study population
----------------

Eighty subjects (65 male and 15 female) were enrolled in this study. They were classified into four groups: group 1 (HCV) comprised of patients with chronic HCV infection (n=20), group 2 (HCV/DM) patients suffering from both HCV and type 2 diabetes (n=18), group 3 (DM) patients with type 2 diabetes (n=22), and group 4 healthy controls (n=20). Patients of groups 2 and 3 were recruited from the National Institute of Diabetes and Endocrinology (NIDE). However, group 1 patients were recruited from the National Institute of Endemic Diseases and Liver, El Kasr El-Einy, Cairo.

Type 2 diabetes was diagnosed according to WHO criteria (WHO, 2006\[[@R31]\]). The duration of diabetes was not more than 4 years in order to exclude any diabetic complications. On the other hand, chronic hepatitis C patients, with or without diabetes, showed abnormal serum aminotransferases for more than 6 months duration and showed positive results when tested for serum anti-HCV antibodies.

The following exclusion criteria were used for all subjects: hypertension, cardiopulmonary disease, renal disease, thyroid dysfunction, malignancy, smokers, alcoholics, other causes of chronic liver disease as chronic hepatitis B, autoimmune hepatitis, acute hepatitis, haemochromatosis, hepatocellular carcinoma, biliary disorders. Patients have previous interferon treatment or recently received any anti-inflammatory drugs were also excluded.

The study was approved by the Research Ethics Committee of the General Organization for Teaching Hospitals and Institutes and the National Research Centre (Approval No. IDEG0147, Date 25/6/2012). All subjects gave written informed consent prior to participation in the study. The study was carried out in accordance with the regulations and recommendations of the Declaration of Helsinki.

A detailed patient\'s history was obtained; body mass index (BMI) was calculated as an index of the weight (in kilograms) divided by the square of the height (in meters) measured on the same day of sample withdrawal.

Overnight fasting blood samples were withdrawn from the antecubital vein. Blood samples were divided into three parts: the first part was collected into 0.5 M EDTA-containing tubes for determination of glycated heamoglobin (HbA1C), the second part was collected into fluoride-containing tubes for determination of FBG and the last part (6 ml) was collected into serum separating tubes for determination of lipid profile, liver function, serological testing (Anti HCV, HBsAG ), insulin and omentin-1 assay. Sera were separated by centrifugation at 3000 rpm for 10 min. Each serum sample was divided into several aliquots and kept at -80 °C until analysis.

Laboratory assessments
----------------------

Serological testing: to exclude HBV infection, hepatitis B surface antigen (HBsAg) was tested in serum by chromatographic immunoassay using rapid test strip (Acon**®** Diagnostics, USA). Anti-HCV antibodies were tested qualitatively by chromatographic immunoassay using rapid test strips provided by Acon**®** Diagnostics, USA. Serum aminotransferase (AST, ALT) were assayed colorimetrically according to Reitman and Frankel Method (Reitman and Frankel, 1957\[[@R23]\]) using kits from Spectrum Diagnostics, Egypt. Fasting blood glucose was determined by colorimetric enzymatic hexokinase method (Siemens Healthcare Diagnostic, USA). Total cholesterol and triacylglycerol were determined by enzymatic colorimetric end point methods (Allain et al., 1974\[[@R1]\]; Fossati and Prencipe, 1982\[[@R10]\]). LDL cholesterol was determined according to heparin/citrate precipitation method and HDL cholesterol was measured according to phosphotungestic acid precipitation method (Burstein et al., 1970\[[@R3]\]; Castelli et al., 1977\[[@R5]\]). All of lipid profile parameters were measured using kits provided by Spectrum Diagnostics, Egypt. HbA1C was determined using HPLC fully automated system with Bio-Rad D-10 Hemoglobin testing system (Jeppsson et al., 1986\[[@R13]\]). All colorimetric and spectrophotometric assays were determined using appropriate semiautomated photometer (JASCO^®^V**-**630UV-Vis Spectrophotometer, USA).

Serum insulin was estimated using insulin enzyme-linked immunosorbant assay (ELISA) kit (DRG Insulin, DRG International Inc., USA) according to the manufacturer\'s protocol. Insulin resistance was determined by the homeostasis model of assessment (HOMA-IR) (Matthews et al., 1985\[[@R18]\]) using the formula: \[fasting blood glucose (mg/dL) X fasting insulin (*μ*IU/mL)\]/405. Beta cell function was determined by (HOMA-β) using the formula:

\[360×fasting insulin (*μ*IU/mL)\] / \[fasting blood glucose (mg/dL) - 63\] %.

Serum omentin-1 concentrations were determined by enzyme-linked immunosorbant assay (ELISA) kit (CUSABIO Biotech Co., USA) according to the manufacturer\'s instructions using ELx808™ Absorbance Microplate Reader, Bio-tek instruments, USA.

Statistical analysis
--------------------

GraphPad Instat™ statistics software (1992-2000 Graph software Inc., V 3.05, Ralf Stahlman, Purdue Univ.931897 S) was used for data analysis. Results were expressed as mean ± SEM. To analyze more than two sets of data, ordinary one way analysis of variance (ANOVA) for parametric data was tried first, followed by Tukey-Kramer multiple comparisons test, when Bartlett\'s test for homogeneity of variance was not-significant. If Bartlett\'s test was significant, logarithmic transformation of the individual data was performed before testing ANOVA again, and then followed by Tukey-Kramer, when Bartlett\'s test became not-significant. If logarithmic transformation did not reduce variability between individual values shown as significant difference of Bartlett\'s test, the comparison was carried out using ANOVA for non-parametric data (Kruskal Wallis test) followed by Dunn\'s test. The difference between groups was considered significant if the probability of error was ≤ 0.05. The correlations between variables were determined by Pearson\'s correlation coefficient. The analysis was repeated using multivariate analysis of covariance (MANCOVA) which was adjusted for age using SPSS software program version 14 (SPSS Inc, Chicago, IL).

Results
=======

Table 1[(Tab. 1)](#T1){ref-type="fig"} displays the demographic data and the studied biochemical parameter for all groups. No significant difference was found among the studied groups in terms of BMI, triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol. However, diabetic and HCV/DM patients were characterized by slightly higher mean age (48.9±1.553 and 45.83±1.952, respectively) compared to the healthy controls and HCV group (38.5±1.8 and 39.4±1.9, respectively).

Chronic hepatitis C patients, either diabetic or non-diabetic, had significantly higher AST and ALT levels compared to both control and diabetic groups as depicted in Table 1[(Tab. 1)](#T1){ref-type="fig"}. The fasting blood glucose levels were increased significantly in diabetic group and HCV/DM group (166.18±17.9 and 149.88±9.8, respectively) compared to control and HCV groups (92.1±2.8 and 94.6±3.33, respectively). On the other hand, insulin levels in diabetic and HCV/DM patients were markedly higher than its levels in HCV patients and control subjects (11.3±1.5 and 9.18±1.19 vs. 7.08±0.6 and 6.9±0.49). However, this increase was statistically significant only in the diabetic group (Table 1[(Tab. 1)](#T1){ref-type="fig"}).

Furthermore, diabetic and HCV/DM groups demonstrated significantly higher HOMA-IR values than the control group (p\<0.001 and p\<0.05, respectively) and HCV group (p \<0.001, p \< 0.05, respectively). Yet, no significant difference was detected among groups concerning the HOMA-β mean values.

The levels of omentin-1 in all studied groups are depicted in Table 1[(Tab. 1)](#T1){ref-type="fig"}. The HCV group demonstrated significantly higher omentin-1 values compared to the control group (p\<0.05). Whereas, after omentin-1 values were adjusted for age, HCV group showed significantly higher omentin-1 values than all other studied groups (Figure 1[(Fig. 1)](#F1){ref-type="fig"}).

Then we evaluated the correlation coefficients of serum omentin-1 with all the studied parameters. Serum omentin-1 levels demonstrated significant positive correlations with AST and ALT levels (r =0.4, p\< 0.001; r =0.423, p\<0.001, respectively) (Figure 2[(Fig. 2)](#F2){ref-type="fig"}). On the other hand, omentin-1 levels revealed significant negative correlation to fasting insulin levels and HOMA-IR (r = - 0.238, p\<0.05; r = - 0.277, p\<0.05, respectively). Furthermore, fasting blood glucose, HbA1c and HOMA-β were negatively correlated to serum omentin-1 levels however those correlations did not reach statistical significance (Table 2[(Tab. 2)](#T2){ref-type="fig"}).

Discussion
==========

Insulin resistance (IR) and type 2 diabetes (T2D) have been demonstrated to be more prevalent among chronic hepatitis C than non infected population (Torres and Harrison, 2008\[[@R28]\]). Despite the close relationship between HCV infection and T2D, the underlying mechanisms of HCV-associated IR and diabetes remain elusive. Adipokines, chemrin and vaspin, have been reported to play a role in the pathogenesis of inflammatory process of CHC and IR caused by HCV (Kukla et al., 2010\[[@R15]\])*.*However, this role is not fully understood.

Omentin-1 (intelectin-1) is a newly identified adipokine that is highly and selectively expressed in visceral adipose tissue (Schäffler et al., 2005\[[@R24]\])*.* Omentin-1 enhances insulin sensitivity and glucose metabolism (Yang et al., 2006\[[@R33]\])*.* Circulating omentin-1 level is elevated in non alcoholic fatty liver disease and is positively correlated with hepatocyte ballooning (Yilmaz et al., 2011\[[@R34]\]). Yet, the role of omentin-1 in liver disorders and their metabolic complications is still ambiguous.

To our knowledge, the current study is the first study exploring the serum omentin-1 levels in chronic hepatitis C patients with or without type 2 diabetes. A salient finding of our study is that serum omentin-1 levels were significantly elevated in HCV patients compared to healthy controls. So it seems that omentin-1 has a role in the pathogenesis of hepatitis. This finding is in agreement with a recent study by Eisinger et al. (2013\[[@R7]\]) showing that omentin-1 is elevated in patients with liver cirrhosis. Another study by Yilmaz and his coworkers (2011\[[@R34]\]), has reported that omentin-1 levels were significantly higher in patients with non alcoholic fatty liver disease than in healthy controls. This finding may be explained, at least partially, by the implication of omentin-1 in immune and inflammatory response. According to growing body of literature, omentin-1 (intelectin-1) is increased during bacterial infection (Tsuji et al., 2009\[[@R29]\]), asthma (Kuperman et al., 2005\[[@R16]\]), and mesothelioma (Wali et al., 2005\[[@R30]\])*.* So it is thought that omentin-1 may play a pivotal role in innate immunity and inflammation. However its exact role is not fully elucidated.

Furthermore, our results demonstrated that age adjusted omentin-1 levels in HCV /DM patients were significantly decreased compared to HCV patients. This may be explained by high glucose and insulin levels in blood of HCV/DM patients compared to HCV patients without diabetes. It has been reported that plasma omentin-1 was declined after prolonged insulin-glucose infusion in healthy individuals. Additionally, treating the human omental tissue explants with glucose and insulin caused down-regulation of omentin-1 expression (Tan et al., 2008\[[@R26]\]). Another study by Gürsoy et al. (2010\[[@R11]\]) has reported that glucose and insulin levels may have a repressive effect on omentin-1 levels.

In the last few years, several studies have reported that omentin-1 levels in type 2 diabetic patients are decreased compared to healthy control (Tan et al., 2008\[[@R27]\]; Pan et al., 2010\[[@R20]\]; Gürsoy et al., 2010\[[@R11]\])*.* In the current study, the diabetic group of patients showed decreased omentin-1 level than healthy controls. Yet, this difference was not statistically significant. This finding is in accordance with a study by El-Mesallamy et al. (2011\[[@R8]\]) reporting that no significant difference was observed in omentin-1 serum levels between the non-obese group with type 2 diabetes, and the non-obese healthy control group (BMI \< 30 kg/m^2^)*.*Notably, all subjects enrolled in our study had normal BMI to avoid the variation in plasma omentin-1 level due to this factor which is one of the major determinants of omentin-1 level as shown by several studies (De Souza Batista et al., 2007\[[@R6]\]; Gürsoy et al., 2010\[[@R11]\]; El-Mesallamy et al., 2011\[[@R8]\])*.*

In accordance with previous studies, our results demonstrated that serum omentin-1 level was negatively correlated with fasting insulin and HOMA-IR (De Souza Batista et al., 2007\[[@R6]\]; Gürsoy et al., 2010\[[@R11]\]; Yan et al., 2011\[[@R32]\])*.* Furthermore, in agreement to what was reported by De Souza Batista et al. (2007\[[@R6]\]) the correlation of omentin-1 level with fasting blood glucose was not significant in the present study. This finding is in opposition to others (Gürsoy et al., 2010\[[@R11]\]; El-Mesallamy et al., 2011\[[@R8]\])*.*

On the other hand, omentin-1 level showed significant positive correlation with liver enzymes AST and ALT. This declares that, omentin-1 level is correlated to the hepatocyte degeneration. This finding is in agreement with a study by Yilmaz et al. (2011\[[@R34]\]) reporting that serum omentin-1 level is positively correlated with C reactive protein and hepatocyte ballooning suggesting an association between omentin-1 and hepatocyte death (Caldwell et al., 2010\[[@R4]\]; Yilmaz et al., 2011\[[@R34]\]). In aforementioned study, they did not correlate the serum omentin-1 level to AST and ALT levels. Additionally, it has been recently reported that omentin-1 induces the apoptosis of hepatocytes by increasing the stability of p53 (Zhang and Zhou, 2013\[[@R35]\]). On the other hand, a recent study by Eisinger et al. (2013\[[@R7]\]) has reported that omentin-1 is not associated with liver function in patients with liver cirrhosis. We have to point out that their study was conducted on liver cirrhosis caused by different etiologies which is different than the current study in which all patients were HCV infected patients.

It is noteworthy that, information about serum omentin-1 levels in chronic hepatitis C patients are scanty and additional larger studies are required to confirm the findings of this study and to identify mechanisms for the paradoxical increase of omentin-1 levels in HCV patients. In conclusion, the salient finding of our study is the increased serum omentin-1 levels in HCV patients compared to the healthy subjects. Furthermore, serum omentin-1 showed significant positive correlation with liver enzymes AST and ALT. Age adjusted omentin-1 values in HCV patients with type 2 diabetes were significantly decreased compared to HCV patients not suffering from diabetes. This decline in omentin-1 levels may be attributed to increased glucose and insulin levels in sera of diabetic patients which have suppressive effect of omentin-1 expression. This indicates that omentin-1 may be implicated in the pathogenesis of hepatitis and its metabolic complications however its role needs to be elucidated by future studies.

Acknowledgement
===============

The authors would like to express their deep appreciation to Prof. Ehsan Hassan, and the staff of National Institute of Endemic Diseases and Liver, Cairo University, for facilitating sample collection. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing interests
===================

The authors declare that they have no competing interests to disclose.

![Demographic data and laboratory characteristics of the studied groups](EXCLI-12-924-t-001){#T1}

![Correlations between omentin-1 levels and other studied parameters](EXCLI-12-924-t-002){#T2}

![Age adjusted serum omentin-1 values in all studied groups. Data are expressed as mean ± SEM.](EXCLI-12-924-g-001){#F1}

![Correlation of serum omentin-1 with ALT (A) and AST (B)](EXCLI-12-924-g-002){#F2}
